Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TK1 | P04183 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TK2 | O00142 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635430 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL1635432 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL30698162 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5982470 | 0.84 | TYMS (0.76) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5872464 | 0.84 | TYMS (0.76) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5982466 | 0.84 | TYMS (0.76) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL13273335 | 0.84 | TYMS (0.76) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5872460 | 0.84 | TYMS (0.76) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL19777590 | 0.84 | TYMS (0.76) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL21067666 | 0.82 | TK1 (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5576429-A | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRICIDE; ANTITUMOR AGENT | MEDIVIR AB (SE) | 1996-11-19 | — | — | US | disclosed |
| EP-0357571-B1 | Pyrimidine nucleosides | MEDIVIR AB (SE) | 1996-04-03 | — | — | EP | disclosed |
| EP-0691333-A2 | Pyrimidine derivatives, process for their preparation and their use as precursors | Medivir Aktiebolag (SE) | 1996-01-10 | — | — | EP | disclosed |
| US-5440040-A | Drug for Aids therapy; viricides | MEDIVIR AB (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0357571-A2 | Pyrimidine nucleosides | Medivir Aktiebolag (SE) | 1990-03-07 | — | — | EP | disclosed |
| WO-1989012061-A1 | PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES | MEDIVIR AB (SE) | 1989-12-14 | — | — | WO | disclosed |